Piper Jaffray Cos. set a $23.00 price objective on Collegium Pharmaceutical Inc. (NASDAQ:COLL) in a research note released on Wednesday. The firm currently has a a buy rating on the specialty pharmaceutical company’s stock.

Several other equities analysts also recently commented on the stock. Jefferies Group restated a buy rating on shares of Collegium Pharmaceutical in a research note on Thursday, September 22nd. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a hold rating to a sell rating in a research note on Monday, August 15th. Needham & Company LLC restated a buy rating and issued a $30.00 price target on shares of Collegium Pharmaceutical in a research note on Wednesday, September 14th. Finally, Gabelli initiated coverage on shares of Collegium Pharmaceutical in a research note on Tuesday, September 13th. They issued a buy rating and a $25.00 price target on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $27.60.

Collegium Pharmaceutical (NASDAQ:COLL) traded up 0.93% on Wednesday, hitting $18.36. 221,116 shares of the stock were exchanged. Collegium Pharmaceutical has a one year low of $8.24 and a one year high of $30.58. The stock’s market capitalization is $431.97 million. The company has a 50 day moving average of $13.29 and a 200 day moving average of $14.54.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.29. On average, equities research analysts forecast that Collegium Pharmaceutical will post ($3.86) earnings per share for the current fiscal year.

In related news, Director John A. Fallon purchased 2,375 shares of the firm’s stock in a transaction dated Friday, August 12th. The shares were purchased at an average cost of $10.59 per share, for a total transaction of $25,151.25. Following the completion of the transaction, the director now directly owns 2,375 shares in the company, valued at approximately $25,151.25. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 37.93% of the company’s stock.

A number of hedge funds have recently modified their holdings of COLL. Nationwide Fund Advisors increased its stake in shares of Collegium Pharmaceutical by 73.3% in the second quarter. Nationwide Fund Advisors now owns 8,665 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 3,665 shares during the last quarter. Alliancebernstein L.P. bought a new stake in shares of Collegium Pharmaceutical during the second quarter valued at $122,000. Royal Bank of Canada increased its stake in shares of Collegium Pharmaceutical by 794.0% in the first quarter. Royal Bank of Canada now owns 11,300 shares of the specialty pharmaceutical company’s stock valued at $205,000 after buying an additional 10,036 shares during the last quarter. Rhumbline Advisers bought a new stake in shares of Collegium Pharmaceutical during the second quarter valued at $143,000. Finally, A.R.T. Advisors LLC bought a new stake in shares of Collegium Pharmaceutical during the second quarter valued at $148,000. 62.13% of the stock is owned by institutional investors and hedge funds.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.

5 Day Chart for NASDAQ:COLL

Receive News & Stock Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.